-
Signature
-
Lisa Lenstrohm, Attorney-in-Fact
-
Issuer symbol
-
IBEX
-
Transactions as of
-
13 Jun 2025
-
Net transactions value
-
-$434,338
-
Form type
-
4
-
Filing time
-
16 Jun 2025, 17:59:34 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Dechant Robert Thomas |
Chief Executive Officer, Director |
C/O IBEX LIMITED, 1717 PENNSYLVANIA AVENUE NW, SUITE 825, WASHINGTON |
Lisa Lenstrohm, Attorney-in-Fact |
16 Jun 2025 |
0001298255 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
IBEX |
Common Shares |
Sale |
$434,338 |
-15,000 |
-7% |
$28.96 |
198,633 |
13 Jun 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: